Vyant Bio, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Cancer Genetics, Inc. Merger (Tables)

Cancer Genetics, Inc. Merger (Tables)

12 Months Ended

Dec. 31, 2022

Business Combination and Asset Acquisition [Abstract]

Schedule of Preliminary Allocation of Purchase Price Consideration

The following details the allocation of the preliminary purchase price consideration recorded on March 30, 2021, the acquisition date, with adjustments recorded through the first quarter of 2022, the end of the purchase price allocation period.

	Preliminary		Adjustments			Final
Assets acquired:
Cash and equivalents	$	30,163	$	-		$	30,163
Accounts receivable		705		-			705
Other current assets		806		227			1,033
Intangible assets		9,500		-			9,500
Fixed assets		416		(256	)		160
Goodwill		22,164		216			22,380
Long-term prepaid expenses and other assets		1,381		-			1,381
Total assets acquired	$	65,135	$	187		$	65,322

Liabilities assumed:
Accounts payable and accrued expenses	$	2,670	$	437		$	3,107
Current liabilities of discontinuing operations		588		(141	)		447
Obligations under operating leases		198		-			198
Obligations under finance leases		106		-			106
Deferred revenue		1,293		(114	)		1,179
Payroll and income taxes payable		360		5			365
Total liabilities assumed	$	5,215	$	187		$	5,402

Net assets acquired	$	59,920	$	-		$	59,920

Schedule of Proforma Financial Information

The following presents the unaudited pro forma combined financial information as if the Merger had occurred as of January 1, 2021:

	Year ended December 31,
	2021
Total revenue	$	6,726
Net loss		(35,623	)
Pro forma loss per common share,		(6.15	)
Pro forma weighted average number of common shares basic and diluted		5,795,498